 Home > Biochemistry News > Biotechnology News > Personalized cancer vaccine development company receives $17 million in financing for clinical treatment of liver cancer

Personalized cancer vaccine development company receives $17 million in financing for clinical treatment of liver cancer

 Last Update: 2022-04-26
 Source: Internet
 Author: User

Tags

als risk factors

exosomes cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On March 24, 2022, Geneos Therapeutics announced the completion of a $17 million Series A financing

Liver cancer is one of the leading causes of cancer-related deaths worldwide

Geneos is committed to developing individualized therapies to unleash the full power of the body's own immune system to fight cancer

GNOS-PV02, developed by GT-EPIC platform, is a neoantigen vaccine based on DNA plasmid delivery

References:

[1] Geneos Therapeutics Secures $17 Million in Series A2 Financing to Advance Personalized Cancer Immunotherapy Platform.

Note: The original text has been deleted

Original title: Express | Focus on liver cancer therapy with positive early clinical results, $17 million to help develop individualized cancer vaccines

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.